Skip to search formSkip to main contentSkip to account menu

VEGF:VEGFR Complex

Known as: VEGF-VEGFR Complex, Vascular Endothelial Growth Factor-Vascular Endothelial Growth Factor Receptor Complex, Vascular Endothelial Growth Factor/Vascular Endothelial Growth Factor Receptor Complex 
A ligand-receptor complex comprised of a homodimer of vascular endothelial growth factor (VEGF) family proteins bound to a heterodimer of vascular… 
National Institutes of Health

Related topics

Related topics

1 relation
Signal Transduction

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2018
Review
2018
Kidney Cancer Research Network of Canada consensus statement on the role of adjuvant therapy after nephrectomy for high-risk, non-metastatic renal cell carcinoma: A comprehensive analysis of the…
INTRODUCTION The Kidney Cancer Research Network of Canada (KCRNC) collaborated to prepare this consensus statement about the use… 
2018
2018
Outcomes of patients (pts) with metastatic clear-cell renal cell carcinoma (mCCRCC) treated with second-line (2L) vascular endothelial growth factor receptor tyrosine kinase inhibitors (VEGFR-TKI…
682Background: Little data exists on objective response rates (ORR), progression-free survival (PFS), and safety of 2L VEGFR-TKI… 
Review
2018
Review
2018
Radiotherapy and Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitors in Renal Cancer
Treatment of metastatic renal cell carcinoma (mRCC) has seen substantial progress over the last decade. A number of targeted… 
2016
2016
Efficacy of cabozantinib (C) vs everolimus (E) in patients (pts) with advanced renal cell carcinoma (RCC) and bone metastases (mets) from the phase III METEOR study.
4558Background: In pts with metastatic RCC, bone mets are prognostic for poor outcomes and represent an unmet medical need. The… 
2015
2015
Prognostic significance of host immune status in patients with late relapsing renal cell carcinoma treated with targeted therapy
We aimed to assess the prognostic role of pretreatment neutrophilia, lymphocytopenia, and neutrophil to lymphocyte ratio (NLR) in… 
Review
2015
Review
2015
Are VEGFR-TKIs effective or safe for patients with advanced non-small cell lung cancer?
Vascular endothelial growth factor receptor tyrosine kinase inhibitors (VEGFR-TKIs) might be new therapeutic strategies for… 
Review
2013
Review
2013
What is the optimal therapy for patients with metastatic renal cell carcinoma who progress on an initial VEGFr-TKI?
Review
2012
Review
2012
Sequential therapy with targeted agents in patients with advanced renal cell carcinoma: optimizing patient benefit.
2011
2011
Final phase II safety and efficacy results of study MC0452: Phase I/II trial of CCI 779 and bevacizumab in advanced renal cell carcinoma.
4548 Background: Combined mTOR and VEGF blockade is a potentially promising and rational strategy for the treatment of advanced… 
2010
2010
VEGFR TKI 'resistance' or transient clinical insensitivity to VEGFR TKI in metastatic renal cell carcinoma.
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)